News
 |
| Su | Mo | Tu | We | Th | Fr | Sa |
|---|---|---|---|---|---|---|
| Su | Mo | Tu | We | Th | Fr | Sa |
|---|---|---|---|---|---|---|
Nov 28, 2023Topline clinical secondary efficacy results and primary safety endpoints from Phase 2b ALS trial (PARADIGM) expected in early December 2023 Patients who completed the 18-month PARADIGM trial,...
- Nov 13, 2023
Clinical efficacy top-line results of PARADIGM, a Phase 2b trial in ALS, expected in December 2023 CAMBRIDGE, Mass., Nov. 13, 2023 /PRNewswire/ -- NeuroSense Therapeutics Ltd. (NASDAQ: NRSN)...
- Nov 9, 2023
- Last patient completed the double-blind segment of PARADIGM, a Phase 2b ALS Trial - Clinical efficacy top-line results from PARADIGM expected in December 2023 CAMBRIDGE, Mass., Nov. 9, 2023...
- Nov 6, 2023
Clinical efficacy results (secondary endpoints) and safety results (primary endpoints) expected December 2023 Biogen collaboration biomarker results expected Q1 2024 Primary biomarker endpoints to...
- Nov 1, 2023
NeuroSense Therapeutics Ltd. (NASDAQ: NRSN) ("NeuroSense"), a company developing treatments for severe neurodegenerative diseases, today announced its Chief Medical Officer Dr. Ferenc Tracik will...
